Medicare will begin covering GLP-1 drugs for weight loss for the first time on July 1, launching a temporary pilot program that lets eligible beneficiaries obtain the popular but costly medications for a flat $50 monthly copay. The move marks a notable shift for a program that has long been barred from paying for treatments prescribed solely to shed pounds.
The initiative, run by the Centers for Medicare and Medicaid Services and known as the Medicare GLP-1 Bridge, will run from July 1, 2026, through the end of 2027. It represents the first time the program will help pay for drugs prescribed purely for obesity, rather than limiting coverage to people taking the medications for conditions such as Type 2 diabetes, cardiovascular disease, sleep apnea or fatty liver disease.
The program exists because of a legal workaround. Under current law, Medicare's prescription-drug benefit, Part D, cannot cover medications prescribed for weight loss, and changing that permanently would require an act of Congress. Instead, CMS is using its authority to run time-limited demonstration projects, standing up the Bridge outside the normal Part D coverage and payment structure, with a central processor handling prior authorizations, claims and payments to pharmacies. Because it operates outside Part D, insurers carry no risk for the drugs and do not have to opt in.
The pilot covers specific weight-loss medications made by the two dominant manufacturers in the category, including injectable and pill forms of one company's flagship product and a newer daily pill and an injection pen from the other. To qualify, beneficiaries must be enrolled in a Medicare drug plan, meet weight and health criteria, and obtain prior authorization, with a prescriber certifying that the drug is being used as part of a diet-and-exercise program. People who already receive a GLP-1 through Part D for an approved condition are not eligible for the Bridge.
The potential reach is substantial. One health-policy research group estimates that roughly 3.8 million Medicare beneficiaries could meet the eligibility requirements, a sizable slice of the program's drug-plan membership. Independent budget analysts have previously projected that broad coverage of anti-obesity medications could cost the federal government tens of billions of dollars over the better part of a decade, though only a fraction of those eligible are expected to start treatment in the near term. The drugs otherwise command cash prices that can run from a few hundred dollars to well over a thousand a month.
There are important caveats. The $50 copay will not count toward a beneficiary's annual deductible or the cap on out-of-pocket drug spending, and the pilot is set to expire at the end of 2027, leaving no clear path for what happens afterward unless officials extend it or Congress changes the law. A broader, longer-term program that would have shifted costs to insurers has been delayed indefinitely. Health experts also note that many patients regain weight after stopping the medications, and that even a $50 monthly cost can be a meaningful barrier for those living on modest fixed incomes.
For the drugmakers, the program opens a large new pool of potential users among older Americans, while for beneficiaries it changes the conversation from whether they can afford treatment to whether the medication is appropriate for them. How many ultimately enroll, and what becomes of the coverage after 2027, will determine the pilot's lasting impact.